|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
CHI's PEP TALK, THE PROTEIN INFORMATION WEEK (Protein Arrays, Protein Informatics, Protein Expression, Human Proteome Project) | ||||||||||||||||
July 19, 2002 | ||||||||||||||||
Cambridge Healthtech Institute, Sheraton San Diego Hotel and Marina, San Diego, California January 13-16, 2003 Genomic and proteomic technologies have rapidly expanded the field of drug discovery. While the majority of drugs on the market are based on an estimated 500 proteins these new technologies have resulted in a surge of new targets. This shifting bottleneck in drug discovery creates new opportunities in protein array manufacturing, protein expression analysis, and protein informatics. The integral component of the human proteome project on setting standards and coordinating efforts is vital for the process to proceed. CHI's Second Annual PEP Talk - The Protein Information Week, scheduled for January 13-16, 2003 in San Diego, California, is designed to bring the technology and research results into one productive format. The week kicks-off with three concurrent technology meetings each is designed to "stand-alone" or attendees can create their own meeting by moving freely between the sessions. The week wraps-up with CHI's Third Annual Human Proteome Project where focus shifts from technology to policy. "As a corporate sponsor of the CHI PepTalk 2002 program, Vivascience was able to make valuable connections as we launched our protein purification technology. If you’re going to be a player in proteomics this is a "must" conference to attend. The level of contacts, intellectual talent, and range of complimentary technology presented was invaluable in helping us bring our new Vivapure products to market." -Tim Fleming, General Manager, Vivascience, Inc. |
||||||||||||||||
Organized by: | CHI | |||||||||||||||
Invited Speakers: | Dr. Ashok R. Dongre, Bristol-Myers Squibb PRI Dr. Harold A. Scheraga, Cornell University Dr. David W. Elrod, Pharmacia Corporation Dr. Steven W. Muchmore, Abbott Laboratories Dr. Emanuel F. Petricoin III, U.S. Food and Drug Administration Dr. Jason H. Moore, Vanderbilt University Medical School Dr. Christian Rohlff, Oxford GlycoSciences (UK) Ltd Dr. Hugh Salamon, Berlex Biosciences |
|||||||||||||||
Deadline for Abstracts: | Poster abstracts: December 13, 2002 | |||||||||||||||
Registration: | Available On-line | |||||||||||||||
E-mail: | eeskedal@healthtech.com | |||||||||||||||
Posted by: | Elaine Eskedal | |||||||||||||||
Host: | wks249.healthtech.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |